Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047618 | 1.00 | TAAR1 (0.59) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL1044827 | 0.98 | TAAR1 (0.61) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL81305 | 0.93 | TAAR1 (0.62) | TAAR1HDAC1HDAC8GAAMEN1 | |
| Bromide SCHEMBL28093819 | 0.91 | TAAR1 (0.61) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL12040551 | 0.86 | TAAR1 (0.62) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL156739 | 0.85 | TAAR1 (0.67) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL30525290 | 0.85 | TAAR1 (0.67) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL9592544 | 0.83 | CYP4F2 (0.49) | TAAR1HDAC1HDAC8CYP4F2CYP4A11 | |
| SCHEMBL7384474 | 0.83 | TAAR1 (0.59) | TAAR1HDAC1HDAC8GAAMEN1 | |
| SCHEMBL2095838 | 0.83 | TAAR1 (0.59) | TAAR1HDAC1HDAC8GAAMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828973-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741875-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759370-B2 | Sphingosine-1-phosphate (SIP) receptor agonists | Praecis Pharmaceuticals (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2046746-A2 | CHEMICAL COMPOUNDS | Praecis Pharmaceuticals Incorporated (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | TAAR1 448/4885HDAC1 2188/4885HDAC8 3575/4885 |
| US-20140221317-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | TAAR1 151/4885HDAC1 2024/4885HDAC8 1438/4885 |
| US-20130157982-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | TAAR1 151/4885HDAC1 2024/4885HDAC8 1438/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | TAAR1 355/4885HDAC1 2068/4885HDAC8 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.